|

Anti-CD56 CAR T Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • The Affiliated Hospital of Xuzhou Medical University1

Indications

  • NK-Cell Leukemia1
  • Extranodal NK/T-cell Lymphoma1
  • Cancer1

Other1 trial

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.